Thursday, May 9, 2013
A group led by researchers at the Memorial Sloan-Kettering Cancer Center has identified a mutation in the androgen receptor that could drive resistance to second-generation
antiandrogen drugs such as
Xtandi enzalutamide. The team's subsequent rational drug design studies
yielded a series of molecules that could overcome the resistance mechanism.1
The next step is determining the relevance
of the F876L mutation in a clinical setting.
Lou, K.-J. SciBX 6(18); doi:10.1038/scibx.2013.429
Published online May 9, 2013
1. Balbas, M.D. et al.
eLife; published online April 9, 2013; doi:10.7554/eLife.00499
Contact: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New
Contact: Yang Shen, Toyota Technological Institute at Chicago, Chicago,
2. Gulley, J. et al.
Clin. Adv. Hematol. Oncol. 1, 49-57 (2003)
3. Brooke, G.N. &
Bevan, C.L. Curr. Genomics 10, 18-25 (2009)
4. Feldman, B.J. &
Feldman, D. Nat. Rev. Cancer 1, 34-45 (2001)
5. Shi, X.-B. et al.
Cancer Res. 62, 1496-1502 (2002)
AND INSTITUTIONS MENTIONED
Aragon Pharmaceuticals Inc., San Diego, Calif.
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
European Medicines Agency, London, U.K.
Food and Drug Administration, Silver Spring, Md.
Howard Hughes Medical Institute, Chevy Chase, Md.
Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Toyota Technological Institute at Chicago, Chicago, Ill.
The University of Chicago, Chicago, Ill.